In its native form, the chemokine CX3CL1 is a firmly adhesive molecule promoting leukocyte adhesion and migration and hence involved, along with its unique receptor CX3CR1, in various inflammatory processes. Here we investigated the role of molecular aggregation in the CX3CL1 adhesiveness. Assays of bioluminescence resonance energy transfer (BRET) and homogeneous time-resolved fluorescence (HTRF) in transfected cell lines and in primary cells showed specific signals indicative of CX3CL1 clustering. Truncation experiments showed that the transmembrane domain played a central role in this aggregation. A chimera with mutations of the 12 central transmembrane domain residues had significantly reduced BRET signals and characteristics of a non-clustering molecule. This mutant was weakly adhesive according to flow and dual pipette adhesion assays and was less glycosylated than CX3CL1, although, as we demonstrated, loss of glycosylation did not affect the CX3CL1 adhesive potency. We postulate that cell surfaces express CX3CL1 as a constitutive oligomer and that this oligomerization is essential for its adhesive potency. Inhibition of CX3CL1 self-assembly could limit the recruitment of CX3CR1-positive cells and may be a new pathway for anti-inflammatory therapies.Migration of circulating leukocytes to injury sites is the first step of the inflammation process, which involves a sequence of coordinated interactions between leukocytes and endothelial cells (1). Central to this physiological and pathological event are chemokines, a family of low molecular weight soluble proteins, that function to attract leukocytes bearing the appropriate receptors (2). Chemokines trigger activation of leukocytes and their firm adhesion to inflamed endothelium, mainly through the mediation of integrins and their cognate ligands (3).Among chemokines, there are two exceptions: CXCL16 and CX3CL1 are type-I membranous proteins. In addition to their chemokine domain (CD), 4 they are composed of a long mucinlike stalk, a transmembrane domain, and a cytoplasmic tail (4, 5) (Fig. 1). The CX3CL1 molecule, with its unique CX3CR1 receptor (6), has been shown to be central in defenses against neurodegenerative disorders (7,8) and against several cancers in murine models (9, 10). The CX3CL1-CX3CR1 axis is also involved in various inflammatory diseases (2), including renal inflammation (11) and atherosclerosis (12, 13). Understanding the structure of this pair of molecules is necessary for exploring pharmacological methods to regulate their activity. The structure of CX3CR1, a receptor of the G protein-coupled receptor (GPCR) family, is relatively well known, but that of CX3CL1 much less so.CX3CL1-CD (76 residues), a globular protein domain 3 nm in diameter (14) and maintained by two disulfide bridges, is structurally similar to other chemokines. It is composed of a disordered N terminus up to the first cysteine (Cys-8), a long loop followed by a three-stranded antiparallel -sheet (residues 24 -51) and a C-terminal ␣-helix (residues 56 -67) packed agains...